Back To: Home : Featured Technology : Microbiome

CLICK HERE FOR WHAT'S NEW IN:
 

Catalent targets biosimilars with UMN Pharma
February 2013
SHARING OPTIONS:

SOMERSET, N.J.—An agreement has been inked between Catalent Pharma Solutions and UMN Pharma Inc. to provide UMN Pharma with a range of biosimilar cell lines through the use of Catalent's proprietary GPEx technology. Per the agreement, UMN and its subsidiary UNIGEN will produce biosimilars using Catalent's GPEx cell lines. Separately, UMN Pharma will assemble an alliance of pharmaceutical companies for product development, including clinical trials, marketing and sales, and plans to begin several biosimilar projects with the allied companies for the Asian market.
 
"There are great synergies between UMN Pharma and Catalent in terms of technologies, business structure, speed and culture. Harnessing Catalent's broad biologics development and cell construction expertise gives UMN Pharma a unique platform to grow our biosimilars business globally," said Masahiro Michishita, executive chairman of UMN Pharma.

Back

PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.